Core Insights - Hoth Therapeutics, Inc. has initiated a study in collaboration with the U.S. Department of Veterans Affairs to evaluate glial cell line-derived neurotrophic factor (GDNF) as a potential first-in-class biologic therapy for obesity and fatty liver disease [1][2]. Study Overview - The program is led by Dr. Srinivasan at the Atlanta VA Medical Center, focusing on GDNF's ability to induce weight loss and resolve fatty liver disease through metabolic and neurotrophic mechanisms [2]. - The study is structured under Aim 1 of the approved Statement of Work (SOW), with positive data potentially supporting IND-enabling development for a biologic addressing obesity and nonalcoholic fatty liver disease (NAFLD), which is a rapidly growing therapeutic market [3]. Timeline and Milestones - Key milestones include: - October 2025: Initiation of high-fat and control diet groups - December 2025: Start of GDNF and comparator dosing - January 2026: Collection of tissue samples and data analysis - Q1 2026: Initial results expected [6]. Company Background - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments aimed at improving patient quality of life, collaborating with scientists and clinicians to explore therapeutics with significant potential [4].